Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance

Novel therapeutic strategies are needed to address the emerging problem of imatinib resistance. The histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) is being evaluated for imatinib-resistant chronic myelogenous leukemia (CML) and has multiple cellular effects, including th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Carew, Jennifer S., Nawrocki, Steffan T., Kahue, Charissa N., Zhang, Hui, Yang, Chunying, Chung, Linda, Houghton, Janet A., Huang, Peng, Giles, Francis J., Cleveland, John L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2007
Assuntos:
Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1896119/
https://ncbi.nlm.nih.gov/pubmed/17363733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-10-050260
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados